Carvykti market report flags faster growth in CAR-T therapies

The Business Research Company says the Carvykti market is set for steady expansion through 2030 as multiple myeloma cases rise, CAR-T adoption widens and manufacturing scales up. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Carvykti sits at the center of a growing market for advanced cancer treatments, especially for patients with relapsed or refractory multiple myeloma. - Demand for CAR-T therapies is rising as traditional myeloma options leave major unmet needs. - The report points to wider regulatory approvals, more treatment centers and better manufacturing capacity as forces that could expand access.

What happened: - The Business Research Company published The Carvykti Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report examines historical growth, forecast trends, key drivers and regional dynamics for the Carvykti market from 2026 to 2030. - Carvykti, also known as ciltacabtagene autoleucel, is a CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have already received at least four prior lines of treatment. - The therapy engineers a patient’s own T cells to target and eliminate plasma cells that express BCMA, or B-cell maturation antigen.

The details: - The market grew in earlier years because traditional myeloma treatments had limitations and early autologous cell therapy results were encouraging. - Other growth drivers included unmet needs in relapsed multiple myeloma, progress in gene modification technology and higher funding for oncology research. - The report expects growth to continue from 2026 to 2030 as multiple myeloma becomes more prevalent and physicians become more familiar with CAR-T protocols. - Broader use of CAR-T therapies across hematologic cancers beyond multiple myeloma is identified as a major trend during the forecast period. - The report also highlights rising interest in personalized cancer treatments and therapies that target BCMA. - Investment in cell therapy production is increasing to improve supply and accessibility. - Oncology care is becoming more centralized around advanced treatment centers. - In 2025, North America held the largest share of the Carvykti market. - The Asia-Pacific region is forecast to be the fastest-growing market segment in the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report frames Carvykti as part of a broader shift from generalized cancer care to highly targeted cell therapies. - Its market case depends less on one product alone and more on the spread of the treatment model, manufacturing scale and specialist infrastructure. - The inclusion of TAM analysis, company scoring, dashboards and hotspot graphics signals that the report is aimed at strategy and investment users, not just clinical readers.

What's next: - The market outlook now depends on whether CAR-T manufacturing can scale fast enough to meet demand. - Wider physician adoption and expanding treatment-center capacity could support faster commercial uptake. - More regional approvals and better access in fast-growing markets such as Asia-Pacific could shift the global mix over time. - More information is available in the full report and a free sample.

The bottom line: - Carvykti is positioned to benefit from the broader push toward CAR-T therapies, with market growth tied to cancer prevalence, specialist care expansion and manufacturing scale-up.